title: Peripheral blood progenitor cell transplantation in 118 patients with hematological malignancies: analysis of factors affecting the rate of engraftment.
abstract: We retrospectively studied the factors affecting the rate of hematopoietic reconstitution (HR) in 118 patients with hematological malignancies who underwent peripheral blood progenitor cell (PBPC) transplantation at a single institution. The patients received a median number of 6.6 x 10(8) nucleated cells/kg corresponding to 9.5 x 10(4) (0.5-578) CFU-GM/kg and 6.8 x 10(6) (0.2-161) CD34-positive cells/kg. The median number of days to reach 500 polymorphonuclear cells/mm3 and 50,000 platelets/mm3 was 12.5 (6-93) and 14.5 (6-440) days, respectively. No patient died from infection during the aplastic phase. By multivariate analysis, we found that the dose of CFU-GM infused was the only factor that significantly affects the HR rate (p < 0.0001). Moreover, patients with acute myelogenous leukemia or those transplanted after busulfan or total-body irradiation conditioning regimens had a slower engraftment (p < 0.08). These results could lead to identifying patients who need growth factors posttransplantation and/or the reinfusion of "back-up" marrow together with PBPC.
authors.affiliation: Bone Marrow Transplant Unit, Hôpital Haut Levêque, CHU Bordeaux, Pessac, France.
authors.forename: J
authors.initials: J
authors.lastname: Reiffers
authors.forename: C
authors.initials: C
authors.lastname: Faberes
authors.forename: J M
authors.initials: JM
authors.lastname: Boiron
authors.forename: G
authors.initials: G
authors.lastname: Marit
authors.forename: C
authors.initials: C
authors.lastname: Foures
authors.forename: A M
authors.initials: AM
authors.lastname: Ferrer
authors.forename: P
authors.initials: P
authors.lastname: Cony-Makhoul
authors.forename: M
authors.initials: M
authors.lastname: Puntous
authors.forename: P
authors.initials: P
authors.lastname: Bernard
authors.forename: G
authors.initials: G
authors.lastname: Vezon
mesh_terms: D000206:Actuarial Analysis; D000293:Adolescent; D000328:Adult; D000368:Aged; D015703:Antigens, CD; D018952:Antigens, CD34; D002648:Child; D003114:Colony-Forming Units Assay; D005260:Female; D006085:Graft Survival; D018380:Hematopoietic Stem Cell Transplantation; D006801:Humans; D007938:Leukemia / Q000401:mortality / Q000628:therapy*; D008223:Lymphoma / Q000401:mortality / Q000628:therapy*; D008297:Male; D008875:Middle Aged; D009101:Multiple Myeloma / Q000401:mortality / Q000628:therapy*; D010976:Platelet Count; D012189:Retrospective Studies; D015996:Survival Rate; D013997:Time Factors
chemical_list: D015703:Antigens, CD; D018952:Antigens, CD34